- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07855770
Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)
A Prospective, Randomized Study on the Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)
The purpose of this study is to evaluate whether a preoperative intraocular gas injection improves visual outcomes in patients with a macula-off rhegmatogenous retinal detachment (RRD). While current surgical therapies successfully reattach the retina, visual recovery can vary. This study will investigate if injecting a small amount of gas (0.3 cc of 100% C3F8) into the eye prior to standard surgery can decrease the duration of macular detachment, reduce retinal displacement, and ultimately result in better final visual acuity compared to the standard of care alone.
Study Overview
Status
Conditions
Detailed Description
Macula-off rhegmatogenous retinal detachment (RRD) is associated with compromised visual outcomes. While current standard-of-care therapies (pars plana vitrectomy and scleral buckle) are highly effective at correcting the anatomy, functional visual recovery remains variable. Time to macular reattachment and the extent of retinal reapposition are critical factors influencing ultimate visual acuity.
Small preliminary studies suggest that an intraocular gas injection performed prior to definitive surgical treatment may decrease the duration of macular detachment and minimize retinal displacement, potentially improving visual outcomes. However, there are currently no randomized controlled trials available to validate this approach.
This randomized study aims to determine if a preoperative injection of 0.3 cc of 100% C3F8 gas prior to standard surgical therapy for macula-off RRD results in superior visual acuity compared to the standard of care alone. By evaluating whether preoperative gas injection effectively shortens the duration of macular separation and reduces retinal displacement, this study seeks to demonstrate a clear visual benefit. Positive findings could change clinical management, establishing a new standard of care and significantly improving the visual prognosis for patients presenting with macula-off RRD.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Omar Masoud, MD
- Phone Number: 4452133130
- Email: omasoud@willseye.org
Study Contact Backup
- Name: Zainab Rustam, MD
- Phone Number: 6674147808
- Email: zrustam2@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Wilmer Eye Institute, Johns Hopkins Hospital
-
Contact:
- Zainab Rustam, MD
- Phone Number: 6674147808
- Email: zrustam2@jhmi.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Wills Eye Hospital
-
Contact:
- Omar Masoud, MD
- Phone Number: 4452133130
- Email: omasoud@willseye.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A patient must meet the following criteria to be eligible for inclusion in the study: 1. Diagnosed with macula-involving primary rhegmatogenous retinal detachment 2. Consents to surgical repair with pars plana vitrectomy with or without scleral buckling 3. Willing and able to comply with clinic visits and study-related procedures
Exclusion Criteria:
- A patient who meets any of the following criteria will be excluded from the study: 1. Age < 18 years old 2. Presence of PVR grade C or worse (as defined by the revised Retina Society PVR classification) at time of surgical repair 3. History of or concurrent ruptured globe, intraocular foreign body, proliferative diabetic retinopathy, retinal vein occlusion, exudative age-related macular degeneration, macular epiretinal membrane, sickle cell disease, uveitis or intraocular infectious diseases 4. Not willing or able to comply with clinic visits and study-related procedures 5. Unable to provide a signed informed consent 6. Unable to maintain positioning to support break 7. Patients that undergo silicone oil placement for primary macula-off RRD 8. For bilateral macula-off RRDs, the better seeing eye will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Preoperative Gas
Patients in this group will be injected with 0.3 cc of 100% C3F8 gas prior to surgical repair of the retinal detachment. |
Patients with Macula off Rhegmatogenous Retinal Detachment will receive an intravitreal injection of 100% C3F8 prior to undergoing surgical repair for their condition Patients with RRD will undergo standard of care treatment of RRD with pars plana vitrectomy or pars plana vitrectomy with scleral buckle |
|
Active Comparator: Standard of Care
Patients in this arm will receive standard of care treatment with Pars Plana Vitrectomy or Pars Plana vitrectomy with Scleral Buckle. |
Patients with RRD will undergo standard of care treatment of RRD with pars plana vitrectomy or pars plana vitrectomy with scleral buckle |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Acuity
Time Frame: 6 months
|
Best Corrected Visual Acuity |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anatomic Success Rate
Time Frame: 6 months
|
Maintenance of retinal attachment and normal retinal structure. Assessed via clinical eye examination, Optical Coherence Tomography Imaging and Fundus autofluorescence. |
6 months
|
|
Ellipsoid Zone disruption
Time Frame: 6 months
|
Examination of presence, and extent of, ellipsoid zone disruption via Optical Coherence Tomography. |
6 months
|
|
Retinal Displacement
Time Frame: 6 months
|
Assessment of presence, and extent, of retinal displacement via clinical eye examination, Optical Coherence Tomography and Fundus autofluorescence |
6 months
|
|
Metamorphopsia
Time Frame: 6 months
|
Assessment of presence, and extent of, metamorphopsia via M-chart examination. |
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ajay Kuriyan, MD, Wills Eye Hospital
- Principal Investigator: Sidra Zafar, MD, The Johns Hopkins Wilmer Eye Institute
Publications and helpful links
General Publications
- Hwang JC. Regional practice patterns for retinal detachment repair in the United States. Am J Ophthalmol. 2012 Jun;153(6):1125-8. doi: 10.1016/j.ajo.2011.11.034. Epub 2012 Feb 8.
- Hillier RJ, Felfeli T, Berger AR, Wong DT, Altomare F, Dai D, Giavedoni LR, Kertes PJ, Kohly RP, Muni RH. The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT). Ophthalmology. 2019 Apr;126(4):531-539. doi: 10.1016/j.ophtha.2018.11.014. Epub 2018 Nov 22.
- Brosh K, Francisconi CLM, Qian J, Sabatino F, Juncal VR, Hillier RJ, Chaudhary V, Berger AR, Giavedoni LR, Wong DT, Altomare F, Kadhim MR, Newsom RB, Marafon SB, Muni RH. Retinal Displacement Following Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment. JAMA Ophthalmol. 2020 Jun 1;138(6):652-659. doi: 10.1001/jamaophthalmol.2020.1046.
- Felfeli T, Mandelcorn MS, Trussart R, Mandelcorn ED. PREOPERATIVE GAS FOR PARS PLANA VITRECTOMY: A SURGICAL TECHNIQUE FOR REPAIR OF RHEGMATOGENOUS RETINAL DETACHMENTS WITH MULTIPLE, LARGE, OR INFERIOR BREAKS. Retin Cases Brief Rep. 2023 Jul 1;17(4):374-379. doi: 10.1097/ICB.0000000000001197. Epub 2021 Sep 27.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB #2025-74
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be shared to protect patient privacy and confidentiality in accordance with HIPAA regulations and Institutional Review Board (IRB) policies. Only aggregate, de-identified data will be reported in peer-reviewed publications.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.